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ABSTRACT
Purpose: Targeted therapy represents an attractive alternative for rare tumors 
such as urachal carcinoma (UrC). The aim of this study was to assess the mutations 
of the most commonly affected 5 genes in the targetable EGFR-pathway in UrC and 
comapre their frequencies to those of found in urothelial and colorectal cancer.
Materials and Methods: Mutational hot-spots of selected genes were tested in 
22 UrC samples by pyrosequencing. Mutational patterns were compared to those 
published for colorectal and urothelial cancers. Furthermore, we sought correlations 
between mutations and clinicopathological and follow-up data.
Results: We found 11 mutations in 10 of 22 (45%) patients. The most frequently 
mutated gene was KRAS (27%) followed by BRAF (18%) and NRAS (5%), while no 
mutations were detected in the EGFR and PIK3CA genes. No correlation was found 
between the mutation status and clinicopathological parameters (Sheldon/Mayo 
stage, tumor grade, metastases). Furthermore, none of the mutations correlated 
with progression-free or overall survival.
Conclusions: The mutation pattern of UrC is more similar to colorectal than to 
urothelial cancer. However, the mutation characteristics of UrC seems to be unique 
suggesting that clinical decision-making for UrC cannot be simply adopted from 
urothelial or colorectal carcinoma. The high occurence of EGFR-pathway mutations 
warrants the testing for KRAS and BRAF mutations when considering anti-EGFR 
therapy in UrC. 
INTRODUCTION
The urachus, or median umbilical ligament, 
is a midline tubular structure stretching between the 
bladder and the umbilicus. It is a remnant of embryonic 
development which gradually degenerates after the 
fourth month of embryonic life [1]. If the regression is 
incomplete, the urachus may persist and give rise to 
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various abnormalities including malignances. Urachal 
cancer (UrC) is a rare, but highly malignant entity 
accounting for < 1% of all bladder cancers and mostly 
detected in conjunction with its invasion to the urinary 
bladder [2]. Because of its low incidence, our knowledge 
on the biology of UrC is limited. The recommended 
treatment for non-metastatic UrC is partial cystectomy 
with the complete removal of umbilicus and umbilical 
ligament [3]. Because of its hidden anatomical location 
at least 30% of UrCs are diagnosed at progressed stages, 
when a surgical treatment is not possible. In these cases, 
the most frequently used treatment is chemotherapy. 
As large scale, prospective clinical studies can hardly 
be performed for such a rare malignancy, clinical 
evidence and clear recommendations are not available 
for the systemic treatment of UrC. Therefore, the 
current chemotherapeutic treatment of UrC is rather 
based on individual decisions. The most frequently used 
chemotherapeutic agents are cisplatin and 5-fluorouracil 
[4-5]. The sparse data available on the efficacy of 
chemotherapeutic treatment in progressed UrC suggests 
5-FU-based treatments to be superior to platinum-based 
therapies [4-5]. However, using any of these therapies the 
survival of UrC patients remains poor, warranting the need 
for more effective treatments. In the lack of evidence-
based recommendations, targeted therapies tailored 
to the genetic features of each UrC case may provide 
an alternative approach in order to rationalize therapy 
decisions. To date there are only few, however promising 
data on the efficacy of targeted therapies in UrC. Testa 
et al. reported a necrotic involution of the tumor and a 
significant improvement of abdominal pain in a UrC 
patient who was treated with second-line multikinase 
inhibitor (Sunitinib) [6], while Goss et al. observed a 
size regression of a UrC as a response to EGFR-inhibitor 
therapy with gefitinib (Iressa) [7]. Finally, a recent study 
reported a patient with lung metastatic UrC who was 
effectively treated with a monoclonal EGFR-inhibitor 
(cetuximab) for eight months [8].
Both developing from the cloaca, urachal 
and colorectal adenocarcinomas (CRC) display 
several similarities regarding their histological, 
immunohistochemical and molecular features [9-10]. 
Mutated intracellular domain of EGFR is a therapeutic 
target in several malignancies including CRC as EGFR-
inhibitors can silence mutation-activated EGFR signaling 
[11]. EGFR has three main downstream pathways: 
(1) RAS-RAF-MAPK, (2) PI3K-AKT and (3) JAK-
STAT pathway, which stimulate mitosis leading to cell 
proliferation and inhibition of apoptosis [12]. A number 
of mutations of these downstream pathways are able to 
impair anti-EGFR treatment [11]. Therefore, mutation 
analyses of the EGFR-pathway are widely used for 
guiding treatment decisions [11, 13].
The prevalence and prognostic significance of the 
mutations in genes of the EGFR pathway in UrC remain 
poorly understood. Therefore, we screened the most 
commonly affected mutational hot spots of KRAS, NRAS, 
BRAF, EGFR and PIK3CA genes in the largest set of 
UrC samples evaluated to date and correlated them with 
patients’ characteristics and survival.
RESULTS
Follow-up characteristics
Postoperative tumor recurrence was detected in two 
cases, metastatic tumor progression in two cases and local 
recurrence together with distant metastatic progression 
in five cases. The median time from surgery to first 
progression was 18 months. At the time of data evaluation 
14 of 22 patients were alive with a median overall survival 
time of 35 months.
Occurrence of mutations
We analyzed the mutations of the most frequently 
affected mutational hot-spots of KRAS, NRAS, BRAF, 
EGFR and PIK3CA genes in 22 UrC samples. 
Overall, 11 mutations in 10 of 22 (45%) patients 
were found. KRAS was the most frequently affected gene 
with 6 mutations (6/22; 27%), followed by BRAF with 4 
mutations (4/22; 18%) and NRAS with one case (1/22; 5%) 
(Table 1, 2). In one case co-occurrence of an NRAS and a 
BRAF mutation was observed. No mutations in the EGFR 
and PIK3CA genes were detected.
Correlation of mutations with the clinical and 
follow-up data
We found no correlation between mutation 
status and clinicopathological parameters (signet ring 
cell differentiation, presence of calcification, Sheldon 
stage, Mayo stage, tumor grade and the presence of 
lymph node or distant metastases). However, all KRAS 
mutations were present in non-metastatic cases (6/18), this 
correlation missed the significance level (p = 0.176 - Chi-
test). Furthermore, no association was detected between 
mutations and progression-free (p = 0.949) and overall 
survival (p = 0.942) (Figure 1).
DISCUSSION
In the present study, we analyzed the mutation 
patterns of the most commonly affected genes of the 
EGFR-signaling pathway in UrC. The observed mutation 
frequencies were compared to those of CRC and urothelial 
carcinoma. Furthermore, we sought correlation between 
the detected genetic alterations and clinicopathological 
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and follow-up data. Our results revealed a unique 
mutational profile for UrC which shows more similarities 
to CRC than to urothelial carcinoma. 
The EGFR signaling pathway represents an 
important therapeutic target in various cancers e.g. in 
metastatic CRC [11]. Regarding efficacy of anti-EGFR 
therapy in UrC we found only one early two studies. 
An early phase I study assessed the effect of the EGFR-
inhibitor gefitinib (Iressa) in various progressed solid 
tumors including lung, breast, colon, cervix and ovary 
cancers as well as one case of lymph node positive UrC 
[7]. From the 28, 22 included cases in this study, four 
showed clinical evidence of response and the one with 
UrC showed the highest decrease in tumor size of 55%, 
which was accompanied by a biological response as 
shown by the decrease of Ki67 proliferation index in the 
post treatment tumor biopsy [7]. In a recent publication 
Collazo-Lorduy et al. reported cetuximab treatment to 
be effective for eight months in a patient with metastatic 
UrC bearing EGFR amplification and wild-type KRAS 
[8]. These promising data suggest that anti-EGFR therapy 
might be effective also in UrC.
Primary resistance to EGFR inhibitors is mostly 
related to the presence of wild-type EGFR, as these 
tumors often harbor mutations in other genes downstream 
of EGFR such as KRAS and BRAF [14]. EGFR mutations 
were found to be absent in urothelial and primary bladder 
ADC and was reported to be also rare in CRC [12, 15-
21]. Our present analysis provided similar results in UrC, 
revealing no mutations in the EGFR gene. 
In the last years it became increasingly evident that 
activating structural mutations in one of the downstream 
pathway members can lead to resistance to anti-EGFR 
therapies (such as cetuximab). One of the most commonly 
affected downstream pathway is the RAS-RAF-MAPK 
signal way. KRAS is a G-protein encoding proto-oncogene 
and a member of the RAS protein family. In contrast to 
wild-type RAS proteins, which are deactivated after 
a short time, mutated RAS proteins cause continuous 
activation of RAS signaling pathways also without 
the upstream stimulation of EGFR or HER1 receptor 
[22, 23]. The oncogenic activation of RAS signaling 
pathways leads to abnormal cell growth, proliferation 
and differentiation. A somatic missense mutation in 
codon 12 of the KRAS gene, results in a single amino acid 
substitution (Gly12Val) representing the most frequently 
occurring mutation in CRC [22]. Further, less frequent 
KRAS mutations were found in KRAS codon 61 and 
146 present in 1.5% and 3.2% of cases [24]. These KRAS 
mutant cases were unlikely to benefit from anti-EGFR 
therapy. Therefore, determination of its mutations has a 
crucial role in characterization and therapy of CRC [23]. 
Table 1: Mutations
Gene Exon Codon Spot change Amino change Gene Exon
KRAS 2 12 c.35G>A p.G12D GGT --> GAT Gly --> Asp 1/22
2 12 c.35G>T p.G12V GGT --> GTT Gly --> Val 1/22
2 13 0/22
3 59 0/22
3 61 c.182A>T p.Q61L CAA --> CTA Gln --> Leu 1/22
4 146 c.437C>T p.A146V GCA --> GTA Ala --> Val 2/22
4 146 c.436G>A p.A146T GCA --> ACA Ala --> Thr 1/22
∑ 6/22
NRAS 2 12, 13 0/22
3 59 0/22
3 61 c.183A>T p.Q61H CAA --> CTA Gln --> His 1/22
4 146 0/22
∑ 1/22
BRAF 15 600 c.1799T>A p.V600E GTG --> GAG Val --> Glu 4/22
EGFR 18 719 0/22
19 744-750 0/22
20 768, 790 0/22
21 858-861 0/22
∑ 0/22
PIK3CA 9 542, 545 0/22
20 1047 0/22
∑ 0/22
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In contrast to CRC [19, 21, 25-28], KRAS mutations are 
rare in urothelial carcinomas and primary bladder ADCs 
(~5% and ~10% respectively) [17-18, 29-32]. In UrC, 
Sirintrapun et al. observed 3 of 7 (43%) cases present with 
KRAS mutation, while Alexander et al. found mutation in 
1 of 5 UrC patients (20%) [18, 33]. In accordance, we 
found similar occurrence (27%) for KRAS mutation in our 
22 patients. Based on these, KRAS mutations - similar to 
CRC but in contrast to urothelial carcinomas - seems to 
be frequent in UrC. However, 3 of the 6 KRAS mutations 
we observed were located at codons 61 and 146 which are 
rarely ( < 5%) affected in CRC. 
About half of the CRC patients with wild-type 
KRAS do not respond to anti-EGFR therapy [34]. In these 
cases, mutated BRAF gene - which is present in ~10% of 
cases - can affect response to anti-EGFR treatment [35]. 
BRAF mutations were found to be absent in urothelial 
carcinoma, while, to best of our knowledge, there are 
no available data on the occurrence of its mutations 
in primary ADC of the bladder [17, 31]. In the present 
analysis, we found BRAF mutations in 4 of 22 (18%) UrC 
cases, which frequency seems to be similar to that of in 
CRC. In contrast, others found no BRAF mutations in UrC 
[8, 33, 36]. Low case number of that study together with 
the relative low abundance of BRAF mutation might be the 
reason for this discrepancy.
NRAS activating mutations were also found to be 
associated with failure of anti-EGFR therapy. Our analysis 
revealed one single UrC with NRAS mutation (1/22, 5%), 
suggesting, that these mutations are rare also in UrC 
similar to those of CRC [19, 21, 27, 31] and urothelial 
carcinoma [17, 30-32] (5% and 1% respectively).
The PIK3CA gene is involved in, the PI3K 
pathway affecting fundamental processes such as protein 
synthesis and cellular growth, mediated by mammalian 
target of rapamycin (mTOR) and S6 kinase. PIK3CA 
Table 2: Mutation frequency in different cancers
Mutations Urachal cc Bladder adenocc Bladder TCC Colorectal cc
N % N % N % N %
KRAS 6/22 * 27 2/21 18 10 10/234 29 4 3410/8350 25 41
3/7 33 43 3/105 30 3 613/1487 26 41
1/5 18 20 4/218 31 2 124/277 19 45
1/7 36 14 4/98 32 4 92/194 27 47
2/9 8 22 0/128 17 0 71/164 28 43
119/276 21 43
Ʃ 13/50 26 2/21 10 21/783 3 4429/10748 41
NRAS 1/22 * 5 2/105 30 2 17/644 37 3
0/7 36 0 0/218 31 0 14/282 19 5
1/9 8 11 4/98 32 4 7/194 27 4
0/128 17 0 25/276 21 9
Ʃ 2/38 5 - - 6/549 1 63/1396 5
BRAF 4/22 * 18 0/145 31 0 1288/11955 35 11
0/7 33 0 0/128 17 0 18/243 19 7
0/7 36 0 10/194 27 5
0/9 8 0 26/164 28 16
22/276 21 8
Ʃ 4/45 9 - - 0/273 0 1342/12832 10
EGFR 0/22 * 0 0/28 18 0 0/21 15 0 17/236 20 7
0/7 36 0 0/75 16 0 3/280 19 1
0/9 8 0 0/128 17 0 11/276 21 4
Ʃ 0/38 0 0/28 0 0/224 0 31/792 4
PIK3CA 0/22 * 0 61/257 41 24 108/743 37 15
0/7 36 0 19/105 30 18 24/255 19 9
1/9 8 11 37/218 31 17 32/194 27 16
26/128 17 20 50/276 21 18
Ʃ 1/38 3 - - 143/708 20 214/1468 15
*results of this study
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Table 3: Patients‘ characteristics and KRAS, NRAS and BRAF mutations
Variables Patients KRAS NRAS BRAF
n % n n n
Age ≤ 55 14 64 4 1 3
> 55 8 44 2 0 1
Gender male 16 73 2 1 4
female 6 27 4 0 0
Histology ADC with SRC 3 14 0 0 1
ADC without SRC 19 86 6 1 3
Calcification present 3 14 1 0 0
absent 19 86 5 1 4
Sheldon Stage I-II 0 0 0 0 0
IIIA 10 45 2 1 2
IIIB 7 32 4 0 1
IIIC 1 5 0 0 0
IVA 2 9 0 0 0
IVB 2 9 0 0 1
IVC 0 0 0 0 0
Mayo stage I 4 19 1 0 0
II 10 48 3 1 3
III 5 24 2 0 0
IV 2 9 0 0 1
missing 1
LN or distant meta at diagn. N0/M0 18 82 6 1 3
N + / M+ 4 18 0 0 1
Initial surgical treatment partial CE 15 68 5 0 3
radical CE 5 23 1 0 0
TURB 2 9 0 1 1
Umbilectomy yes 11 50 4 0 2
no 11 50 2 1 2
LND yes 13 59 3 0 2
no 9 41 3 1 2
Chemotherapy yes 6 27 1 1 2
no 16 73 5 0 2
Progression local recurrence 2 9 1 1 1
distant met 2 9 1 0 0
both 5 23 2 0 1
no progression 13 59 3 0 2
Abbreviations:
ADC – adenocarcinoma
SRC – signet ring cell differentiation+
CE – cystectomy
LND – lymph node dissection
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mutations in CRC are associated with clinical resistance 
to EGFR-targeted monoclonal antibodies [38]. Another 
therapeutically relevant correlation between the PIK3CA 
mutation and treatment response is related to aspirin. 
Experimental results demonstrated, that the inhibition of 
cyclooxygenase-2 (COX-2) by aspirin also down-regulates 
PI3K signaling activity [39]. In accordance, PIK3CA 
mutant CRCs were found to benefit from adjuvant aspirin 
therapy in contrast to patients with wild-type PIK3CA 
gene [40]. We found no PIK3CA mutations in any of the 
analyzed UrCs. In contrast, both urothelial [17, 30-31] and 
colorectal cancers [19, 21, 27, 31] were reported to bear 
PIK3CA mutations with a probability of 15-20% (Table 
2 3).
We found no significant correlation between the 
mutation status and clinicopathological parameters of UrC 
(signet ring cell differentiation, presence of calcification, 
Sheldon stage, Mayo stage, tumor grade and the presence 
of lymph node or distant metastases). KRAS mutations 
were present only in non-metastatic cases (6/18), however, 
this correlation missed the significance level (p = 0.176 - 
Chi-test). Furthermore, none of the mutations correlated 
with progression-free or overall survival. In contrast, 
Sirantrapun et al. recently analyzed KRAS and BRAF 
mutations in 7 cases of UrC and found a better survival in 
patients with mutated KRAS gene [33]. This observation, 
however, is in contrast to those made in CRC and lung 
adenocarcinoma where KRAS mutations were associated 
with adverse prognosis. Therefore, the observed favorable 
prognostic effect of KRAS in UrC seems rather to be a 
consequence of low patient numbers than a real prognostic 
effect.
Recent publications provided whole exome 
sequencing data in samples UrC patients. Singh et al. 
identified recurrent mutations in NF1, APC and RNF43 
genes suggesting the involvement of MAPK and Wnt/β-
catenin pathways in UrC formation [36]. In accordance, 
a further study found mutations in the MAPK pathway in 
four of nine cases [8]. 
Our study has some limitations regarding the low 
number of analyzed cases. Because of the extreme low 
incidence of UrC, only multi-institutional efforts can help 
to reach statistically relevant sample sizes. Being aware 
of this problem, we collected samples from multiple 
university centers. However, despite our study is one of 
the largest to date with molecular analysis on UrC, we 
have to acknowledge the sample size is still low, which 
does not allow a reliable statistical analysis. Therefore, 
further analyses with larger patient numbers are needed to 
confirm our findings. 
CONCLUSIONS
Our comparison between the mutation patterns of 
UrC and CRC as well as urothelial carcinoma revealed 
both similarities and differences. On the one hand, 
KRAS and BRAF mutations occurred in UrC with similar 
frequencies as in CRC, in contrast to urothelial carcinoma, 
where both of these mutations are infrequent. On the 
other hand, unlike in CRC, PIK3CA mutations seem to 
be absent. Finally, EGFR and NRAS mutations are rare 
in all these three tumor entities. These data suggest that 
the molecular features of UrC are rather similar to CRC 
than to urothelial carcinoma. However, the mutation 
characteristics of UrC seems to be unique, suggesting, 
that clinical decision making regarding UrC cannot 
simply adopted from evidence that is based on colorectal 
or urothelial carcinoma. Furthermore, our data suggest that 
Figure 1: Kaplan-Meier survival curves
Oncotarget39299www.impactjournals.com/oncotarget
patients with metastatic UrC, who are being considered for 
an anti-EGFR antibody therapy, should be tested for the 
presence of KRAS and BRAF mutations prior to therapy.
MATERIALS AND METHODS
Clinical samples
Twenty-two formalin-fixed, paraffin-embedded 
(FFPE) UrC samples were retrospectively collected 
from four academic centers. Inclusion criteria were 
histologically confirmed urachal adenocarcinoma localized 
to the urachus fistula and/or bladder dome. Cases with 
metastatic and/or local invasion to the bladder from other 
(e.g. gastrointestinal) cancers were excluded. 
Clinical data including age, gender, tumor 
localization, Sheldon/Mayo-stage, grade, lymph node 
status and presence of distant metastasis, details on 
treatment, tumor recurrence, progression and survival 
were obtained from the medical records and relevant 
offices. 
The median patient age was 52 years (range: 32-77 
years). Sixteen of 22 patients were men (female-to-male 
ratio: 1:2.7). In three cases signet ring cell morphology 
and in another three cases calcification was observed. 
We used both the Sheldon [42] and Mayo systems [3] 
for stage classification. According to the Sheldon staging 
system [14], 10 patients were categorized into Sheldon 
stage IIIA, 7 into IIIB, 1 into IIIC, 2 into IVA and 1 into 
IVB, while the distribution regarding to the Mayo-system 
[3] was as follows: 4x stage I, 10x stage II, 5x stage III 
and 7x stage IV (staging data from one patient was not 
available). At the time of diagnosis, 4 patients (18%) had 
lymph node or distant metastasis. Initial surgical treatment 
was partial cystectomy in 15, radical cystectomy in 5 
and transurethral resection (TURB) in 2 cases. In the 
two patients who underwent TURB, cystectomy was 
performed within a few weeks following transurethral 
resection. Eleven patients underwent umbilectomy and 
13 patients had lymphadenectomy. Six patients received 
chemotherapy (Table 3 1). No chemotherapy or radiation 
was performed before surgery in any of the cases. The 
study was performed in accordance with the ethical 
standards of the Helsinki Declaration and was approved 
by the local ethical committee. 
DNA isolation and mutation analysis
Tumor containing areas were marked on 
hematoxylin and eosin (HE) stained sections by a 
pathologist and careful macrodissection has been 
performed in order to reduce contamination with non-
malignant tissue. DNA was isolated from the dissected 
tissue sample using the High Pure PCR Template 
Preparation Kit (Roche, Mannheim, Germany) according 
to the manufacturer’s recommendation. Extracted DNA 
concentrations were measured by a NanoDrop ND-1000 
Spectrophotometer V3.3 (Thermo Fisher Scientific, 
Wilmington, DE, USA). Isolated DNA samples were 
amplified by polymerase chain reaction (PCR) for 13 
exons of the 5 selected genes (KRAS exons 2, 3 and 4; 
NRAS exons 2, 3 and 4; BRAF exon 15; EGFR exons 18, 
19, 20 and 21 and PIK3CA exons 9 and 20) on an Applied 
Biosystems VeritiTM 96 well Thermal Cycler instrument 
(Applied Biosystems, Foster City, CA, USA). PCR 
conditions are shown in Suppl. table 1. PCR amplification 
products were analyzed on a PyroMark Q24 analyzer 
(Qiagen, Hilden, Germany) with PyroMark Q24 Software 
2.0. All mutations were confirmed in a second analysis 
by repeating the PCR and pyrosequencing steps from 
the same DNA sample. Pyrosequencing primers were 
designed to test codons 12, 13, 59, 61 and 146 for KRAS, 
codons 12, 13, 59, 61, 117 and 146 for NRAS, codon 600 
for BRAF, codons 719, 744-750, 768, 790 and 858-861 for 
EGFR and codons 542, 545 and 1047 for PIK3CA. Primer 
sequences are listed in Suppl. table 2.
Statistical analysis
Results were correlated with clinicopathological 
and follow-up data. Chi-squared test was used to 
evaluate the association between mutation status and 
clinicopathological parameters. The Kaplan-Meier method 
with log-rank test was performed to estimate overall 
and progression-free survival. Statistical analyses were 
performed using the SPSS software version 20.0 (SPSS, 
Chicago, IL). The statistical significance was set at p < 
0.05.
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